Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 11/8/24 → 12/21/30 |
Funding
- Novartis (domestic): $15,945.00
Rapcabtagene: A Phase 2, Adaptive, Randomized, Open-Label, Assessor-Blinded Active-Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel vs. SOC in Patients Suffering from Systemic Lupus Erythematosus (SLE) with Active, Refractor
- Piranavan, Paramarajan (PI)
- Ahmed, Sadiq (CoI)
- Alkilany, Reem (CoI)
- Qasrawi, Ayman (CoI)